RICHLAND, Wash., Aug. 16, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will present at the Rodman & Renshaw 18th Annual Global Investment Conference taking place on September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.
Tom LaVoy, CEO, Brien Ragle, CFO, and Bill Cavanagh, COO, will be attending the conference and will present a corporate overview, including a review of the Company’s growth strategy and financial results for the fiscal year ended June 30, 2016, which management intends to release as part of the Company’s Form 10-K filing prior to the conference.
Management will present on Tuesday, September 13, 2016 at 10:00 am ET and will be available for one-on-one meetings throughout the conference as well. A live webcast of the presentation will be available at http://wsw.com/webcast/rrshq26/isr. For those who are not available to listen to the live webcast, a replay will be archived at the above link for 180 days following the live event, as well as on the Company’s website at http://www.isoray.com/shareholder-presentations/.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the proposed timing of the filing of the Company’s Form 10-K for the fiscal year ended June 30, 2016, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the timing of the preparation of the Form 10-K, completion of management, accounting and legal review of the Form 10-K, and other risks detailed from time to time in IsoRay’s reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.